EGCG treatment in RA patients inhibits IL-1β induced IL-6 production by synovial fibroblasts and can upregulate an inhibitor, i.e., soluble gp130 receptor, which in turn suppresses IL-6 trans signaling (170). This evidence concerns the gene IL1B and rheumatoid arthritis.